NeoGenomics Executive Compensation

Director and Former Chief Executive Officer

FY2025$310,962$3.4M$3.7M

Chief Commercial Officer

FY2025$630,069$2.2M$2.9M

Chief Financial Officer

FY2025$603,731$2.3M$2.9M

Alicia Olivo

Executive Vice President General Counsel and Business Development

FY2025$522,500$1.5M$2.0M

Chief Operations Officer and Former President Oncology Data Solutions

FY2025$269,231$1.7M$1.9M

Gary Passman

Chief Culture Officer

FY2025$447,962$1.1M$1.6M

Vishal Sikri

President Advanced Diagnostics

FY2024$246,208$941,892$1.2M

Compensation Analysis

Computed directly from SEC-sourced figures tracked on this page — not a general description.

NeoGenomics discloses FY2025 compensation for 8 named executive officers, totaling $20.7M. Tony Zook, the Director and Chief Executive Officer, accounts for 22% of that combined total.

Cash compensation (salary plus bonus) made up 18% of NeoGenomics's FY2025 tracked executive pay, with stock awards accounting for 82%. That's notably more stock-weighted than the typical Healthcare company in this dataset, where stock awards average 0% of tracked pay.

Among 78 other Healthcare companies in this dataset, NeoGenomics's combined tracked executive pay of $20.7M ranks in the 69th percentile (industry median: $12.5M). Its highest-paid executive, Tony Zook, ranks in the 45th percentile for top-executive pay in the sector (industry median: $6.3M).

Historical Compensation Data

ExecutiveYearBaseStockTotal

Tony Zook

FY2025$601,539$4.0M$4.6M

FY2025$310,962$3.4M$3.7M

FY2025$630,069$2.2M$2.9M

FY2025$603,731$2.3M$2.9M

Alicia Olivo

FY2025$522,500$1.5M$2.0M

FY2025$269,231$1.7M$1.9M

Gary Passman

FY2025$447,962$1.1M$1.6M

FY2024$1.0M$5.9M$6.9M

FY2024$540,346$1.6M$2.1M

FY2024$562,516$1.4M$1.9M

FY2024$559,975$1.2M$1.8M

Alicia Olivo

FY2024$512,672$863,357$1.4M

Vishal Sikri

FY2024$246,208$941,892$1.2M

FY2023$1.0M$6.0M$7.0M

FY2023$525,000$1.9M$2.4M

FY2023$525,000$1.6M$2.1M